Teladoc Health (NYSE:TDOC) PT Lowered to $21.00

Teladoc Health (NYSE:TDOC) had its target price reduced by Oppenheimer from $26.00 to $21.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the health services provider’s stock. Oppenheimer’s price target indicates a potential upside of 61.41% from the company’s previous close.

Other research analysts have also issued research reports about the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research report on Friday. DA Davidson lowered their target price on shares of Teladoc Health from $22.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 21st. Evercore ISI lowered their target price on shares of Teladoc Health from $15.00 to $14.00 and set an “in-line” rating on the stock in a research note on Friday. Citigroup lowered their target price on shares of Teladoc Health from $21.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 21st. Finally, Barclays lowered their target price on shares of Teladoc Health from $25.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Teladoc Health presently has an average rating of “Hold” and an average target price of $19.67.

Teladoc Health Stock Down 2.4 %

Teladoc Health stock opened at $13.01 on Friday. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -9.23 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.54 and a quick ratio of 3.47. Teladoc Health has a fifty-two week low of $12.65 and a fifty-two week high of $30.41. The firm has a fifty day moving average price of $14.85 and a two-hundred day moving average price of $17.72.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). The company had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.37) EPS. As a group, analysts forecast that Teladoc Health will post -1.07 earnings per share for the current year.

Insider Activity

In other news, CMO Stephany Verstraete sold 7,945 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total transaction of $115,361.40. Following the sale, the chief marketing officer now directly owns 56,486 shares of the company’s stock, valued at $820,176.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CMO Stephany Verstraete sold 7,945 shares of the stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $14.52, for a total value of $115,361.40. Following the transaction, the chief marketing officer now directly owns 56,486 shares in the company, valued at $820,176.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Willem Waters sold 4,523 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $19.18, for a total transaction of $86,751.14. Following the completion of the transaction, the chief operating officer now owns 38,570 shares in the company, valued at $739,772.60. The disclosure for this sale can be found here. Insiders have sold 135,441 shares of company stock valued at $2,038,251 over the last three months. 1.63% of the stock is owned by insiders.

Institutional Investors Weigh In On Teladoc Health

Several hedge funds have recently bought and sold shares of TDOC. Vanguard Group Inc. raised its holdings in Teladoc Health by 11.8% in the fourth quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock worth $377,451,000 after purchasing an additional 1,855,480 shares during the period. ARK Investment Management LLC raised its holdings in Teladoc Health by 4.5% in the fourth quarter. ARK Investment Management LLC now owns 21,224,565 shares of the health services provider’s stock worth $457,389,000 after purchasing an additional 912,692 shares during the period. Dimensional Fund Advisors LP raised its holdings in Teladoc Health by 25.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,834,422 shares of the health services provider’s stock worth $82,636,000 after purchasing an additional 767,999 shares during the period. Norges Bank acquired a new stake in Teladoc Health in the fourth quarter worth $9,714,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Teladoc Health by 37.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,549,585 shares of the health services provider’s stock worth $28,807,000 after purchasing an additional 418,909 shares during the period. 76.82% of the stock is currently owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.